Literature DB >> 28825215

Risk factors in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk childhood acute leukemia.

Dong-Mei Han1, Xiao-Li Zheng1, Li Ding1, Hong-Min Yan1, Zhi-Dong Wang1, Mei Xue1, Ling Zhu1, Jing Liu1, Heng-Xiang Wang2.   

Abstract

In the present study, we sought to analyze the risk factors following haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in children with high-risk acute leukemia. We retrospectively reviewed data from 73 children with high-risk leukemia. Univariate and multivariate analyses were performed to evaluate relationships between variables and patient outcomes. The mean time for neutrophil engraftment was significantly shorter in children given a graft with a higher number of nucleated cells (>10.13 × 108/kg vs ≤10.13 × 108/kg: 13.79 ± 2.73 vs 17.71 ± 3.90 days, P < 0.001) and in younger children (≤10 years vs >10 years: 14.21 ± 3.12 vs 17.71 ± 3.90 days, P < 0.001). Time to platelet engraftment was clearly shorter in children given a graft with higher number of nucleated cells (>10.13 × 108/kg vs ≤10.13 × 108/kg: 12.12 ± 8.62 vs 32.1 ± 24.83 days, P < 0.028). Overall survival was 64.6 ± 9.1%, 41.1 ± 10.1%, and 81.6 ± 9.6%, respectively, in children with HR-ALL in CR1, ALL in CR2-4, and AML (P = 0.012). The number of total nucleated cells was significantly associated with transplant-related mortality (TRM). We suggest that outcomes of haplo-HSCT may be improved by increased infusion of nucleated cells.

Entities:  

Keywords:  Haploidentical hematopoietic stem cell transplantation; High-risk childhood acute leukemia; Risk analysis

Mesh:

Year:  2017        PMID: 28825215     DOI: 10.1007/s12185-017-2317-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  24 in total

1.  Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.

Authors:  André Schrauder; Alfred Reiter; Helmut Gadner; Dietrich Niethammer; Thomas Klingebiel; Bernhard Kremens; Christina Peters; Wolfram Ebell; Martin Zimmermann; Felix Niggli; Wolf-Dieter Ludwig; Hansjörg Riehm; Karl Welte; Martin Schrappe
Journal:  J Clin Oncol       Date:  2006-12-20       Impact factor: 44.544

2.  Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants.

Authors:  Kristin M Page; Lijun Zhang; Adam Mendizabal; Stephen Wease; Shelly Carter; Tracy Gentry; Andrew E Balber; Joanne Kurtzberg
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-28       Impact factor: 5.742

3.  Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study.

Authors:  Valentino Conter; Maria Grazia Valsecchi; Rosanna Parasole; Maria Caterina Putti; Franco Locatelli; Elena Barisone; Luca Lo Nigro; Nicola Santoro; Maurizio Aricò; Ottavio Ziino; Andrea Pession; Anna Maria Testi; Concetta Micalizzi; Fiorina Casale; Marco Zecca; Gabriella Casazza; Paolo Tamaro; Gaetano La Barba; Lucia Dora Notarangelo; Daniela Silvestri; Antonella Colombini; Carmelo Rizzari; Andrea Biondi; Giuseppe Masera; Giuseppe Basso
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

4.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.

Authors:  M J Laughlin; J Barker; B Bambach; O N Koc; D A Rizzieri; J E Wagner; S L Gerson; H M Lazarus; M Cairo; C E Stevens; P Rubinstein; J Kurtzberg
Journal:  N Engl J Med       Date:  2001-06-14       Impact factor: 91.245

5.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

Authors:  Dao-Pei Lu; Lujia Dong; Tong Wu; Xiao-Jun Huang; Mei-Jie Zhang; Wei Han; Huan Chen; Dai-Hong Liu; Zhi-Yong Gao; Yu-Hong Chen; Lan-Ping Xu; Yao-Chen Zhang; Han-Yun Ren; Dan Li; Kai-Yan Liu
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

6.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.

Authors:  F Aversa; A Tabilio; A Velardi; I Cunningham; A Terenzi; F Falzetti; L Ruggeri; G Barbabietola; C Aristei; P Latini; Y Reisner; M F Martelli
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

7.  High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

Authors:  Stefan O Ciurea; Marcos de Lima; Pedro Cano; Martin Korbling; Sergio Giralt; Elizabeth J Shpall; Xuemei Wang; Peter F Thall; Richard E Champlin; Marcelo Fernandez-Vina
Journal:  Transplantation       Date:  2009-10-27       Impact factor: 4.939

8.  Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group.

Authors:  Thomas Klingebiel; Jacqueline Cornish; Myriam Labopin; Franco Locatelli; Philippe Darbyshire; Rupert Handgretinger; Adriana Balduzzi; Joanna Owoc-Lempach; Franca Fagioli; Reuven Or; Christina Peters; Franco Aversa; Emmanuelle Polge; Giorgio Dini; Vanderson Rocha
Journal:  Blood       Date:  2009-12-29       Impact factor: 22.113

9.  Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia.

Authors:  Peter Lang; Rupert Handgretinger; Dietrich Niethammer; Paul G Schlegel; Michael Schumm; Johann Greil; Peter Bader; Corinna Engel; Hans Scheel-Walter; Matthias Eyrich; Thomas Klingebiel
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

10.  Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Huan Chen; Wei Han; Yu-Hong Chen; Xiao-Hui Zhang; Dao-Pei Lu
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742

View more
  3 in total

1.  Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients.

Authors:  Li Ding; Dong-Mei Han; Hong-Min Yan; Jie-Xin Zhou; Xiao-Li Zheng; Ling Zhu; Mei Xue; Jing Liu; Ning Mao; Zi-Kuan Guo; Hong-Mei Ning; Heng-Xiang Wang; Heng Zhu
Journal:  Bone Marrow Transplant       Date:  2022-04-25       Impact factor: 5.174

2.  Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation.

Authors:  Ran Zhang; Xuan Lu; Liang V Tang; Huafang Wang; Han Yan; Yong You; Zhaodong Zhong; Wei Shi; Linghui Xia
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

3.  A study of human leukocyte antigen-haploidentical hematopoietic stem cells transplantation combined with allogenic mesenchymal stem cell infusion for treatment of severe aplastic anemia in pediatric and adolescent patients.

Authors:  Li Ding; Dong-Mei Han; Xiao-Li Zheng; Hong-Min Yan; Mei Xue; Jing Liu; Ling Zhu; Sheng Li; Ning Mao; Zi-Kuan Guo; Hong-Mei Ning; Heng-Xiang Wang; Heng Zhu
Journal:  Stem Cells Transl Med       Date:  2020-09-25       Impact factor: 6.940

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.